Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...

Eli Lilly shares have underperformed the broader market over the past year, but Wall Street analysts remain firmly bullish in ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Wegovy and Zepbound - except the weight regain is worse, because of the extreme way in which these medications suppress your ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

Lilly's valuation seems reasonable given its growth prospects. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

In their zeal to “Make America Healthy Again,” Trump administration officials are making statements that some advocacy and ...